Article
Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.
Melanoma research - 1 Oct 2026
Tarhini Ahmad A, Khaksar Mohammad Ali, Chen Zhihua, Lee Sandra J, Hodi F Stephen, Li Tingyi, Yoder Sean J, Streicher Howard, Hwu Patrick, Sondak Vernon K, Kirkwood John M, Wang Xuefeng, Kanetsky Peter A
Abstract excerpt
Immune checkpoint inhibitor (ICI)-mediated dermatitis is a common treatment-related adverse event. We conducted single-nucleotide polymorphisms (SNPs)-array genotyping on germline DNA from 744 participants in a phase three adjuvant trial of ipilimumab in melanoma. Logistic regression was used to estimate associations between inherited genetic markers and the occurrence of dermatitis. We also tested previously...
Topics
Join the communities discussing this publication.